Drugs / B7-H3 CAR T cells
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07172958 | Jan 2026 → Dec 2035 expected | Ewing sarcoma, Wilms tumor, neuroblastoma, rhabdomyosarcoma | Children's National Research Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT07222735 | Jan 2026 → Nov 2030 expected | Ewing sarcoma, pediatric osteosarcoma, rhabdomyosarcoma | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT05835687 | Apr 2023 → Jun 2026 overdue | atypical teratoid rhabdoid tumor, diffuse midline glioma, H3 K27M-mutant, ependymoma, glioblastoma +1 | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04897321 | Jul 2022 → Mar 2027 expected | Ewing sarcoma, Wilms tumor, adrenal cortex carcinoma, childhood malignant neoplasm +10 | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | B7-H3 CAR+ T cells | “This is a phase I dose-escalation study to determine the safety and feasibility of autologous CAR-TA T cells (B7-H3 CAR+ T cells administered with DNR-PRAME Tumor...” NCT07172958 ↗ |
| Modality | Cell therapy | “autologous T cells genetically engineered to express B7-H3-CARs” NCT04897321 ↗ |
| Route | Intravenous | “The study participant will receive B7-H3-CAR T cells by vein, through either an IV or a central line.” NCT04897321 ↗ |